Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhenkun Ma

Showing results (1-10 of 67) with videos related to

Pageof 7
Sort By:
Infectious Disorders Drug Targets|November 1, 2007
Mycobacterium tuberculosis DNA gyrase as a target for drug discoveryKhisimuzi Mdluli, Zhenkun Ma
Clinics in Chest Medicine|November 21, 2009
Toward an optimized therapy for tuberculosis? Drugs in clinical trials and in preclinical developmentZhenkun Ma, Christian Lienhardt
Current Opinion in Pharmacology|September 27, 2002
Ketolides: the future of the macrolides?Angela M Nilius, Zhenkun Ma
Journal of Medicinal Chemistry|June 24, 2016
Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial InfectionsZhenkun Ma, Anthony Simon Lynch
Future Medicinal Chemistry|September 2, 2011
Drug repositioning in the treatment of malaria and TBAlexis Nzila, Zhenkun Ma, Kelly Chibale
The Journal of Antibiotics|June 24, 2003
Novel 12-membered ring macrolides with activity against erythromycin-resistant organismsPeter A Nemoto, Xiaolin Zhang, Stevan Djuric, et al.
Organic Letters|March 15, 2002
Regioselective synthesis of bifunctional macrolides for probing ribosomal bindingZhenkun Ma, Leping Li, Michael Rupp, et al.
Organic Letters|February 25, 2005
Short and efficient synthesis of a vinyl-substituted tricyclic erythromycin derivativeRobert F Keyes, Justin J Carter, Xiaolin Zhang, et al.
Lancet (London, England)|May 22, 2010
Global tuberculosis drug development pipeline: the need and the realityZhenkun Ma, Christian Lienhardt, Helen McIlleron, et al.
Bioorganic & Medicinal Chemistry Letters|September 11, 2007
Preparation and in vitro anti-staphylococcal activity of novel 11-deoxy-11-hydroxyiminorifamycinsJing Li, Zhenkun Ma, Katrina Chapo, et al.
Pageof 7

Showing results (1-10 of 67) with videos related to

Sort By:
Pageof 7
Infectious Disorders Drug Targets|November 1, 2007
Mycobacterium tuberculosis DNA gyrase as a target for drug discoveryKhisimuzi Mdluli, Zhenkun Ma
Clinics in Chest Medicine|November 21, 2009
Toward an optimized therapy for tuberculosis? Drugs in clinical trials and in preclinical developmentZhenkun Ma, Christian Lienhardt
Current Opinion in Pharmacology|September 27, 2002
Ketolides: the future of the macrolides?Angela M Nilius, Zhenkun Ma
Journal of Medicinal Chemistry|June 24, 2016
Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial InfectionsZhenkun Ma, Anthony Simon Lynch
Future Medicinal Chemistry|September 2, 2011
Drug repositioning in the treatment of malaria and TBAlexis Nzila, Zhenkun Ma, Kelly Chibale
The Journal of Antibiotics|June 24, 2003
Novel 12-membered ring macrolides with activity against erythromycin-resistant organismsPeter A Nemoto, Xiaolin Zhang, Stevan Djuric, et al.
Organic Letters|March 15, 2002
Regioselective synthesis of bifunctional macrolides for probing ribosomal bindingZhenkun Ma, Leping Li, Michael Rupp, et al.
Organic Letters|February 25, 2005
Short and efficient synthesis of a vinyl-substituted tricyclic erythromycin derivativeRobert F Keyes, Justin J Carter, Xiaolin Zhang, et al.
Lancet (London, England)|May 22, 2010
Global tuberculosis drug development pipeline: the need and the realityZhenkun Ma, Christian Lienhardt, Helen McIlleron, et al.
Bioorganic & Medicinal Chemistry Letters|September 11, 2007
Preparation and in vitro anti-staphylococcal activity of novel 11-deoxy-11-hydroxyiminorifamycinsJing Li, Zhenkun Ma, Katrina Chapo, et al.
Pageof 7